EGFR and non-small cell lung carcinoma: We hypothesize that targeting cell cycle processes with nutlin‐3, or protein ubiquitination processes with carfilzomib, might be promising new clinical strategies to overcome resistance to EGFR inhibitor drugs in NSCLC.